Lv5
1568 积分 2025-11-28 加入
Enabling Access to sp3‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling
8天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
23天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
1个月前
已完结
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
3个月前
已完结
Development of Scalable Synthesis of RAS Inhibitor’s Indole Building Block via Flow Chemistry
3个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 3: Optimization of the Deprotection Reaction and the Crystallization for the Final Step of API Synthesis
3个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 2: Synthesis of the Malonamide Core and the Final Intermediate
3个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 1: Synthesis of the Diol Fragment
3个月前
已完结
Process Development of the Novel LpxC Inhibitor T-1228. Part 4: Control of Mutagenic Impurities during API Synthesis
3个月前
已完结
皖公网安备34019202002308
